Zoetis (ZTS) to Release Earnings on Thursday

Key Points

• Zoetis will report Q1 2026 results before the market opens on Thursday, May 7 (8:30 AM ET); analysts expect $1.61 EPS and $2.3066 billion in revenue, and the company has set FY2026 guidance of $7.00–$7.10 EPS.
• In the prior quarter Zoetis beat estimates with $1.48 EPS (vs. $1.40 expected) and $2.39 billion in revenue, and analysts project roughly $7 EPS for the current year and $8 EPS for next year.
• Zoetis announced a quarterly dividend of $0.53 ($2.12 annualized, ~1.9% yield); the stock trades around a 19x P/E with a consensus analyst rating of "Hold" and a $151.75 target.

Zoetis (NYSE:ZTS - Get Free Report) is projected to post its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect Zoetis to post earnings of $1.61 per share and revenue of $2.3066 billion for the quarter. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Interested persons may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:30 AM ET.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. The business had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The business's quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.40 EPS. On average, analysts expect Zoetis to post $7 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Zoetis Stock Performance

NYSE:ZTS opened at $113.97 on Thursday. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The firm has a market capitalization of $47.94 billion, a price-to-earnings ratio of 18.93, a PEG ratio of 1.80 and a beta of 0.98. The firm's fifty day simple moving average is $120.17 and its 200 day simple moving average is $124.86. Zoetis has a twelve month low of $112.97 and a twelve month high of $172.23.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be issued a dividend of $0.53 per share. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.9%. Zoetis's payout ratio is presently 35.22%.

Analyst Ratings Changes

Several research firms recently weighed in on ZTS. Bank of America lifted their target price on shares of Zoetis from $135.00 to $140.00 and gave the company a "neutral" rating in a report on Friday, February 13th. BTIG Research restated a "buy" rating and set a $160.00 target price on shares of Zoetis in a report on Thursday, February 26th. Citigroup began coverage on shares of Zoetis in a report on Wednesday, April 15th. They set a "buy" rating and a $145.00 target price on the stock. Leerink Partners restated a "market perform" rating on shares of Zoetis in a report on Tuesday, March 10th. Finally, UBS Group reduced their target price on shares of Zoetis from $136.00 to $130.00 and set a "neutral" rating on the stock in a report on Tuesday. Seven research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Zoetis presently has an average rating of "Hold" and a consensus target price of $151.75.

Hedge Funds Weigh In On Zoetis

A number of institutional investors have recently added to or reduced their stakes in the company. State Street Corp lifted its holdings in Zoetis by 0.8% in the 4th quarter. State Street Corp now owns 19,796,891 shares of the company's stock worth $2,490,845,000 after buying an additional 149,382 shares in the last quarter. Amundi increased its position in shares of Zoetis by 51.2% in the 4th quarter. Amundi now owns 4,001,317 shares of the company's stock worth $503,445,000 after purchasing an additional 1,354,581 shares during the last quarter. Invesco Ltd. increased its position in shares of Zoetis by 4.6% in the 3rd quarter. Invesco Ltd. now owns 3,371,032 shares of the company's stock worth $493,249,000 after purchasing an additional 147,271 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Zoetis by 1.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,834,486 shares of the company's stock worth $356,649,000 after purchasing an additional 41,639 shares during the last quarter. Finally, Corient Private Wealth LLC increased its position in shares of Zoetis by 85.9% in the 2nd quarter. Corient Private Wealth LLC now owns 2,578,593 shares of the company's stock worth $400,619,000 after purchasing an additional 1,191,840 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

About Zoetis

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.